Chris J L M Meijer

List of Publications by Year
in descending order

280 papers	41,396 citations	6613 79 h-index	2385 198 g-index
282 all docs	282 docs citations	282 times ranked	20912 citing authors

#	Article	IF	Citations
1	Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Journal of Pathology, 1999, 189, 12-19.	4.5	7,095
2	Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. New England Journal of Medicine, 2003, 348, 518-527.	27.0	5,264
3	Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncology, The, 2010, 11, 1048-1056.	10.7	2,093
4	Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet, The, 2014, 383, 524-532.	13.7	1,282
5	Human Papillomavirus and Oral Cancer: The International Agency for Research on Cancer Multicenter Study. Journal of the National Cancer Institute, 2003, 95, 1772-1783.	6.3	1,013
6	Overview of the European and North American studies on HPV testing in primary cervical cancer screening. International Journal of Cancer, 2006, 119, 1095-1101.	5.1	922
7	Against which human papillomavirus types shall we vaccinate and screen? the international perspective. International Journal of Cancer, 2004, 111, 278-285.	5.1	912
8	Primary and secondary cutaneous CD30+lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood, 2000, 95, 3653-3661.	1.4	741
9	Male Circumcision, Penile Human Papillomavirus Infection, and Cervical Cancer in Female Partners. New England Journal of Medicine, 2002, 346, 1105-1112.	27.0	707
10	Evidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical Cancer. Vaccine, 2012, 30, F88-F99.	3.8	695
11	A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. International Journal of Cancer, 2007, 121, 2465-2472.	5.1	658
12	Sexually Transmitted Infection as a Cause of Anal Cancer. New England Journal of Medicine, 1997, 337, 1350-1358.	27.0	635
13	Relation of human papilloma virus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet, The, 1999, 354, 20-25.	13.7	627
14	Worldwide Human Papillomavirus Etiology of Cervical Adenocarcinoma and Its Cofactors: Implications for Screening and Prevention. Journal of the National Cancer Institute, 2006, 98, 303-315.	6.3	568
15	Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. International Journal of Cancer, 2009, 124, 516-520.	5.1	557
16	Overview of Human Papillomavirus-Based and Other Novel Options for Cervical Cancer Screening in Developed and Developing Countries. Vaccine, 2008, 26, K29-K41.	3.8	526
17	GP5+/6+ PCR followed by Reverse Line Blot Analysis Enables Rapid and High-Throughput Identification of Human Papillomavirus Genotypes. Journal of Clinical Microbiology, 2002, 40, 779-787.	3.9	484
18	Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncology, The, 2012, 13, 78-88.	10.7	431

#	Article	IF	Citations
19	Chapter 9: Clinical applications of HPV testing: A summary of meta-analyses. Vaccine, 2006, 24, S78-S89.	3.8	393
20	Genetic Patterns in Head and Neck Cancers That Contain or Lack Transcriptionally Active Human Papillomavirus. Journal of the National Cancer Institute, 2004, 96, 998-1006.	6.3	378
21	HPVâ€mediated cervical carcinogenesis: concepts and clinical implications. Journal of Pathology, 2006, 208, 152-164.	4.5	360
22	The presence of persistent high-risk hpv genotypes in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months. International Journal of Cancer, 1995, 61, 306-311.	5.1	344
23	Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nature Reviews Cancer, 2014, 14, 395-405.	28.4	295
24	Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. International Journal of Cancer, 2001, 93, 232-235.	5.1	277
25	Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: The age-related patterns for high-risk and low-risk types. International Journal of Cancer, 2000, 87, 221-227.	5.1	243
26	Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is ageâ€dependent. International Journal of Cancer, 1993, 53, 919-923.	5.1	242
27	HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ: British Medical Journal, 2010, 340, c1040-c1040.	2.3	240
28	The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. Journal of Pathology, 2003, 201, 1-6.	4.5	232
29	POBASCAM, a populationâ€based randomized controlled trial for implementation of highâ€risk HPV testing in cervical screening: Design, methods and baseline data of 44,102 women. International Journal of Cancer, 2004, 110, 94-101.	5.1	230
30	Human papillomavirus 16 load in normal and abnormal cervical scrapes: An indicator of CIN II/III and viral clearance. International Journal of Cancer, 2002, 98, 590-595.	5.1	219
31	Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Molecular Cancer, 2010, 9, 167.	19.2	217
32	Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival. International Journal of Cancer, 2006, 119, 1078-1081.	5.1	214
33	Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet, The, 2001, 358, 1782-1783.	13.7	210
34	Highâ€risk HPV testing on selfâ€sampled versus clinicianâ€collected specimens: A review on the clinical accuracy and impact on population attendance in cervical cancer screening. International Journal of Cancer, 2013, 132, 2223-2236.	5.1	210
35	The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. British Journal of Haematology, 2001, 112, 950-958.	2.5	200
36	TSLC1 Gene Silencing in Cervical Cancer Cell Lines and Cervical Neoplasia. Journal of the National Cancer Institute, 2004, 96, 294-305.	6.3	194

#	Article	IF	Citations
37	Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncology, The, 2011, 12, 441-450.	10.7	182
38	Evaluation of 14 triage strategies for HPV DNAâ€positive women in populationâ€based cervical screening. International Journal of Cancer, 2012, 130, 602-610.	5.1	179
39	Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm. International Journal of Cancer, 2013, 132, 1565-1571.	5.1	177
40	Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: A randomized clinical trial. International Journal of Cancer, 2003, 107, 811-816.	5.1	171
41	Intraâ€operative rapid diagnostic method based on CK19 mRNA expression for the detection of lymph node metastases in breast cancer. International Journal of Cancer, 2008, 122, 2562-2567.	5.1	167
42	HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nature Reviews Clinical Oncology, 2016, 13, 119-132.	27.6	154
43	Human Papillomavirus-16 Is the Predominant Type Etiologically Involved in Penile Squamous Cell Carcinoma. Journal of Clinical Oncology, 2007, 25, 4550-4556.	1.6	147
44	Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncology, The, 2014, 15, 315-322.	10.7	147
45	Evidence for at least three alternative mechanisms targeting the p16INK4A/cyclin D/Rb pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus. Journal of Pathology, 2003, 201, 109-118.	4.5	145
46	Human papillomavirus testing on selfâ€sampled cervicovaginal brushes: An effective alternative to protect nonresponders in cervical screening programs. International Journal of Cancer, 2007, 120, 1505-1510.	5.1	145
47	Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?. Blood, 2002, 99, 232-237.	1.4	138
48	CD4+CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. International Journal of Cancer, 2007, 121, 1749-1755.	5.1	134
49	The presence of highâ€risk HPV combined with specific p53 and p16^{INK4a} expression patterns points to highâ€risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. Journal of Pathology, 2003, 201, 535-543.	4.5	133
50	Most Primary Cutaneous CD30-Positive Lymphoproliferative Disorders Have a CD4-Positive Cytotoxic T-Cell Phenotype. Journal of Investigative Dermatology, 1997, 109, 636-640.	0.7	131
51	Factors affecting transmission of mucosal human papillomavirus. Lancet Infectious Diseases, The, 2010, 10, 862-874.	9.1	131
52	Acquisition and Persistence of Human Papillomavirus Infection in Younger Men: A Prospective Follow-up Study among Danish Soldiers. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1528-1533.	2.5	130
53	HPV-mediated transformation of the anogenital tract. Journal of Clinical Virology, 2005, 32, 25-33.	3.1	130
54	Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial. Lancet Oncology, The, 2019, 20, 229-238.	10.7	129

#	Article	IF	Citations
55	Human papillomavirus and risk factors for cervical cancer in Chennai, India: A caseâ€control study. International Journal of Cancer, 2003, 107, 127-133.	5.1	126
56	Do HPV-negative cervical carcinomas exist?. , 1997, 181, 253-254.		125
57	Cervical cancer in the Netherlands 1989-1998: Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. International Journal of Cancer, 2005, 113, 1005-1009.	5.1	120
58	Combined Promoter Methylation Analysis of CADM1 and MAL: An Objective Triage Tool for High-Risk Human Papillomavirus DNAâ€“Positive Women. Clinical Cancer Research, 2011, 17, 2459-2465.	7.0	119
59	Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood, 2002, 99, 4540-4546.	1.4	118
60	New Technologies and Procedures for Cervical Cancer Screening. Vaccine, 2012, 30, F107-F116.	3.8	117
61	2020 list of human papillomavirus assays suitable for primary cervical cancer screening. Clinical Microbiology and Infection, 2021, 27, 1083-1095.	6.0	116
62	Concordance of Specific Human Papillomavirus Types in Sex Partners Is More Prevalent than Would Be Expected by Chance and Is Associated with Increased Viral Loads. Clinical Infectious Diseases, 2005, 41, 612-620.	5.8	112
63	Monitoring of Epstein-Barr Virus DNA Load in Peripheral Blood by Quantitative Competitive PCR. Journal of Clinical Microbiology, 1999, 37, 2852-2857.	3.9	111
64	Prevalence of mucosotropic human papillomaviruses in squamous-cell carcinomas of the head and neck. , 1996, 66, 464-469.		110
65	ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects-a review. Journal of Pathology, 2003, 200, 4-15.	4.5	103
66	Experience with highâ€risk human papillomavirus testing on vaginal brushâ€based selfâ€samples of nonâ€attendees of the cervical screening program. International Journal of Cancer, 2012, 130, 1128-1135.	5.1	101
67	CADM1andMALpromoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. International Journal of Cancer, 2013, 133, 1293-1299.	5.1	100
68	Clinical Progression of High-Grade Cervical Intraepithelial Neoplasia: Estimating the Time to Preclinical Cervical Cancer From Doubly Censored National Registry Data. American Journal of Epidemiology, 2013, 178, 1161-1169.	3.4	100
69	Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology. International Journal of Cancer, 2006, 119, 1102-1107.	5.1	99
70	Analysis of cytomorphologically abnormal cervical scrapes for the presence of 27 mucosotropic human papillomavirus genotypes, using polymerase chain reaction. International Journal of Cancer, 1994, 56, 802-806.	5.1	98
71	Condom use promotes regression of human papillomavirus-associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia. International Journal of Cancer, 2003, 107, 804-810.	5.1	98
72	Role of Epstein-Barr Virus DNA Load Monitoring in Prevention and Early Detection of Post-transplant Lymphoproliferative Disease. Leukemia and Lymphoma, 2002, 43, 831-840.	1.3	97

#	Article	IF	Citations
73	High-risk human papillomavirus testing versus cytology in predicting post-treatment disease in women treated for high-grade cervical disease: A systematic review and meta-analysis. Gynecologic Oncology, 2012, 125, 500-507.	1.4	97
74	Methylation Analysis of the FAM19A4 Gene in Cervical Scrapes Is Highly Efficient in Detecting Cervical Carcinomas and Advanced CIN2/3 Lesions. Cancer Prevention Research, 2014, 7, 1251-1257.	1.5	97
75	Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis. Journal of Pathology, 2009, 219, 327-336.	4.5	95
76	Penile lesions and human papillomavirus in male sexual partners of women with cervical intraepithelial neoplasia. Journal of the American Academy of Dermatology, 2002, 47, 351-357.	1.2	88
77	Combined CADM1 and MAL promoter methylation analysis to detect (preâ€)malignant cervical lesions in highâ€risk HPVâ€positive women. International Journal of Cancer, 2011, 129, 2218-2225.	5.1	87
78	Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands. BMJ, The, 2016, 355, i4924.	6.0	86
79	CADM1, MAL and miR124-2 methylation analysis in cervical scrapes to detect cervical and endometrial cancer. Journal of Clinical Pathology, 2014, 67, 1067-1071.	2.0	82
80	Primary hrHPV DNA Testing in Cervical Cancer Screening: How to Manage Screen-Positive Women? A POBASCAM Trial Substudy. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 55-63.	2.5	82
81	High Concordance of Results of Testing for Human Papillomavirus in Cervicovaginal Samples Collected by Two Methods, with Comparison of a Novel Self-Sampling Device to a Conventional Endocervical Brush. Journal of Clinical Microbiology, 2006, 44, 2518-2523.	3.9	81
82	Human papillomavirus in early laryngeal carcinoma. Laryngoscope, 2009, 119, 1531-1537.	2.0	81
83	Anal and penile high-risk human papillomavirus prevalence in HIV-negative and HIV-infected MSM. Aids, 2013, 27, 2921-2931.	2.2	80
84	Validation of the FAM19A4 / mir124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women. Gynecologic Oncology, 2016, 141, 341-347.	1.4	80
85	Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. International Journal of Cancer, 2000, 88, 92-98.	5.1	79
86	Human papilloma virus in head and neck cancer: The need for a standardised assay to assess the full clinical importance. European Journal of Cancer, 2009, 45, 2935-2939.	2.8	77
87	Focal aberrations indicate EYA2 and hsaâ€miRâ€375 as oncogene and tumor suppressor in cervical carcinogenesis. Genes Chromosomes and Cancer, 2013, 52, 56-68.	2.8	76
88	Mailed, Home-Obtained Urine Specimens: a Reliable Screening Approach for Detecting Asymptomatic Chlamydia trachomatis Infections. Journal of Clinical Microbiology, 1999, 37, 976-980.	3.9	73
89	High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance. Journal of Pathology, 2001, 195, 300-306.	4.5	72
90	Increased Risk of HIV Acquisition among Kenyan Men with Human Papillomavirus Infection. Journal of Infectious Diseases, 2010, 201, 1677-1685.	4.0	72

#	Article	IF	Citations
91	Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors. Cancer Gene Therapy, 2001, 8, 342-351.	4.6	71
92	Reasons for non-attendance to cervical screening and preferences for HPV self-sampling in Dutch women. Preventive Medicine, 2014, 64, 108-113.	3.4	70
93	A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine, 2016, 34, 4205-4212.	3.8	68
94	Genome-wide DNA Methylation Profiling Reveals Methylation Markers Associated with 3q Gain for Detection of Cervical Precancer and Cancer. Clinical Cancer Research, 2017, 23, 3813-3822.	7.0	68
95	Telomerase Suppression by Chromosome 6 in a Human Papillomavirus Type 16-Immortalized Keratinocyte Cell Line and in a Cervical Cancer Cell Line. Journal of the National Cancer Institute, 2001, 93, 865-872.	6.3	67
96	Methylation-mediated transcriptional repression of microRNAs during cervical carcinogenesis. Epigenetics, 2013, 8, 220-228.	2.7	67
97	HPV Detection Methods. Disease Markers, 2007, 23, 273-281.	1.3	66
98	Model-Based Estimation of Viral Transmissibility and Infection-Induced Resistance From the Age-Dependent Prevalence of Infection for 14 High-Risk Types of Human Papillomavirus. American Journal of Epidemiology, 2010, 171, 817-825.	3.4	66
99	Comprehensive analysis of human papillomavirus prevalence and the potential role of low-risk types in verrucous carcinoma. Modern Pathology, 2012, 25, 1354-1363.	5.5	66
100	Offering self-sampling for human papillomavirus testing to non-attendees of the cervical screening programme: Characteristics of the responders. European Journal of Cancer, 2012, 48, 1799-1808.	2.8	66
101	Seroreactivity to Human Papillomavirus Type 16 Virusâ€like Particles Is Lower in Highâ€Risk Men than in Highâ€Risk Women. Journal of Infectious Diseases, 1997, 176, 876-883.	4.0	63
102	HPV testing can reduce the number of follow-up visits in women treated for cervical intraepithelial neoplasia grade 3. Gynecologic Oncology, 2003, 91, 67-73.	1.4	63
103	Cervical cancer risk in HPVâ€positive women after a negative FAM19A4/mir124â€2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year followâ€up. International Journal of Cancer, 2018, 143, 1541-1548.	5.1	63
104	HPV16 and increased risk of recurrence after treatment for CIN. Gynecologic Oncology, 2007, 104, 273-275.	1.4	62
105	Long-term Impact of Human Papillomavirus Vaccination on Infection Rates, Cervical Abnormalities, and Cancer Incidence. Epidemiology, 2011, 22, 505-515.	2.7	62
106	Prevalence of human papillomavirus in women with invasive cervical carcinoma by HIV status in Kenya and South Africa. International Journal of Cancer, 2012, 131, 949-955.	5.1	62
107	Triaging <scp>HPV</scp>â€positive women with normal cytology by p16/<scp>K</scp>iâ€67 dualâ€stained cytology testing: Baseline and longitudinal data. International Journal of Cancer, 2015, 136, 2361-2368.	5.1	61
108	A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening. International Journal of Cancer, 2006, 118, 791-796.	5.1	60

#	Article	IF	Citations
109	Human Papillomavirus Type-Specific 18-Month Risk of High-Grade Cervical Intraepithelial Neoplasia in Women with a Normal or Borderline/Mildly Dyskaryotic Smear. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1268-1273.	2.5	60
110	Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in highâ€risk HPVâ€positive women of a gynecologic outpatient population (COMETH study). International Journal of Cancer, 2016, 138, 992-1002.	5.1	60
111	HPV16 semiquantitative viral load and serologic biomarkers in oral and oropharyngeal squamous cell carcinomas. International Journal of Cancer, 2005, 115, 329-332.	5.1	59
112	Highâ€risk human papillomavirus DNA load in a populationâ€based cervical screening cohort in relation to the detection of highâ€grade cervical intraepithelial neoplasia and cervical cancer. International Journal of Cancer, 2009, 124, 381-386.	5.1	59
113	Genomic profiling identifies common HPV-associated chromosomal alterations in squamous cell carcinomas of cervix and head and neck. BMC Medical Genomics, 2009, 2, 32.	1.5	56
114	Oral human papillomavirus infection in HIV-negative and HIV-infected MSM. Aids, 2013, 27, 2117-2128.	2.2	56
115	Methylation markers <scp>FAM19A4</scp> and <scp>miR124</scp>â€2 as triage strategy for primary human papillomavirus screen positive women: A large European multicenter study. International Journal of Cancer, 2021, 148, 396-405.	5.1	56
116	Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. International Journal of Cancer, 2007, 121, 361-367.	5.1	55
117	FAM19A4 methylation analysis in self-samples compared with cervical scrapes for detecting cervical (pre)cancer in HPV-positive women. British Journal of Cancer, 2016, 115, 579-587.	6.4	55
118	Identification and Validation of a 3-Gene Methylation Classifier for HPV-Based Cervical Screening on Self-Samples. Clinical Cancer Research, 2018, 24, 3456-3464.	7.0	55
119	Development of a multiplex methylation-specific PCR as candidate triage test for women with an HPV-positive cervical scrape. BMC Cancer, 2012, 12, 551.	2.6	54
120	Different risk factor patterns for high-grade and low-grade intraepithelial lesions on the cervix among HPV-positive and HPV-negative young women. , 1998, 76, 613-619.		53
121	Chromosomal Signatures of a Subset of High-Grade Premalignant Cervical Lesions Closely Resemble Invasive Carcinomas. Cancer Research, 2009, 69, 647-655.	0.9	53
122	hTERT promoter activity and CpG methylation in HPV-induced carcinogenesis. BMC Cancer, 2010, 10, 271.	2.6	53
123	Adverse Effects of Activated Cytotoxic T Lymphocytes on the Clinical Outcome of Nodal Anaplastic Large Cell Lymphoma. Blood, 1999, 93, 2688-2696.	1.4	51
124	Male circumcision is associated with a lower prevalence of human papillomavirusâ€associated penile lesions among Kenyan men. International Journal of Cancer, 2012, 130, 1888-1897.	5.1	51
125	Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse. International Journal of Cancer, 2005, 117, 177-181.	5.1	50
126	Methods for HPV detection in exfoliated cell and tissue specimens. Apmis, 2010, 118, 520-528.	2.0	50

#	Article	IF	Citations
127	Risk factors for HPV infection in women from sexually transmitted disease clinics: Comparison between two areas with different cervical cancer incidence. , 1998, 75, 1-8.		49
128	Differential expression of human Polycomb group proteins in various tissues and cell types. Journal of Cellular Biochemistry, 2001, 81, 129-143.	2.6	49
129	Evaluation of p16/Ki-67 dual-stained cytology as triage test for high-risk human papillomavirus-positive women. Modern Pathology, 2017, 30, 1021-1031.	5.5	49
130	HPV-associated flat penile lesions in men of a non-STD hospital population: Less frequent and smaller in size than in male sexual partners of women with CIN. International Journal of Cancer, 2005, 113, 36-41.	5.1	48
131	Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: A multi-regional health economic analysis. Vaccine, 2008, 26, F46-F58.	3.8	48
132	Methylation-specific digital karyotyping of HPV16E6E7-expressing human keratinocytes identifies novel methylation events in cervical carcinogenesis. Journal of Pathology, 2013, 231, 53-62.	4.5	48
133	Experience with HPV self-sampling and clinician-based sampling in women attending routine cervical screening in the Netherlands. Preventive Medicine, 2019, 125, 5-11.	3.4	48
134	Pathologic analysis of sentinel lymph nodes. Journal of Surgical Oncology, 2001, 20, 238-245.	1.4	47
135	Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis. International Journal of Cancer, 2006, 118, 1759-1768.	5.1	47
136	PIK3CA-mediated PI3-kinase signalling is essential for HPV-induced transformation in vitro. Molecular Cancer, 2011, 10, 71.	19.2	47
137	Viral E6-E7 Transcription in the Basal Layer of Organotypic Cultures without Apparent p21cip1 Protein Precedes Immortalization of Human Papillomavirus Type 16- and 18-Transfected Human Keratinocytes. Journal of Virology, 1998, 72, 749-757.	3.4	47
138	Methylation marker analysis and HPV16/18 genotyping in high-risk HPV positive self-sampled specimens to identify women with high grade CIN or cervical cancer. Gynecologic Oncology, 2014, 135, 58-63.	1.4	45
139	Management of high-risk HPV-positive women for detection of cervical (pre)cancer. Expert Review of Molecular Diagnostics, 2016, 16, 961-974.	3.1	45
140	p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population. Modern Pathology, 2016, 29, 870-878.	5.5	43
141	Host-cell DNA methylation patterns during high-risk HPV-induced carcinogenesis reveal a heterogeneous nature of cervical pre-cancer. Epigenetics, 2018, 13, 769-778.	2.7	43
142	No direct role for Epstein-Barr virus in oral carcinogenesis: A study at the DNA, RNA and protein levels. , 2000, 86, 356-361.		42
143	High numbers of active caspase 3â€“positive Reed-Sternberg cells in pretreatment biopsy specimens of patients with Hodgkin disease predict favorable clinical outcome. Blood, 2002, 100, 36-42.	1.4	42
144	Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands. Vaccine, 2007, 25, 6245-6256.	3.8	41

#	Article	IF	Citations
145	Brush-based self-sampling in combination with GP5+/6+-PCR-based hrHPV testing: High concordance with physician-taken cervical scrapes for HPV genotyping and detection of high-grade CIN. Journal of Clinical Virology, 2012, 54, 147-151.	3.1	40
146	Correlation between viral load, multiplicity of infection, and persistence of HPV16 and HPV18 infection in a Dutch cohort of young women. Journal of Clinical Virology, 2016, 83, 6-11.	3.1	40
147	FAM19A4/miR124â€2 methylation in invasive cervical cancer: A retrospective crossâ€sectional worldwide study. International Journal of Cancer, 2020, 147, 1215-1221.	5.1	40
148	Down-Regulation of GATA-3 Expression during Human Papillomavirus-Mediated Immortalization and Cervical Carcinogenesis. American Journal of Pathology, 2002, 160, 1945-1951.	3.8	39
149	Flat penile lesions: The infectious â€œinvisibleâ€•link in the transmission of human papillomavirus. International Journal of Cancer, 2006, 119, 2505-2512.	5.1	39
150	HPV16/18 vaccination to prevent cervical cancer in The Netherlands: Modelâ€based costâ€effectiveness. International Journal of Cancer, 2009, 124, 970-978.	5.1	39
151	Combined CADM1/MAL Methylation and Cytology Testing for Colposcopy Triage of High-Risk HPV-Positive Women. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1933-1937.	2.5	39
152	Presence of human papillomavirus in semen in relation to semen quality. Human Reproduction, 2016, 31, dev317.	0.9	39
153	Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. , 1999, 189, 12.		39
154	Genotyping of Chlamydia trachomatis in Urine Specimens Will Facilitate Large Epidemiological Studies. Journal of Clinical Microbiology, 1998, 36, 3077-3078.	3.9	38
155	Prevalence and risk factors of human papillomavirus infection by penile site in uncircumcised Kenyan men. International Journal of Cancer, 2010, 126, 572-577.	5.1	37
156	Chromosomal profiles of highâ€grade cervical intraepithelial neoplasia relate to duration of preceding highâ€risk human papillomavirus infection. International Journal of Cancer, 2012, 131, E579-85.	5.1	37
157	HPV E4 expression and DNA hypermethylation of CADM1, MAL, and miR124-2 genes in cervical cancer and precursor lesions. Modern Pathology, 2018, 31, 1842-1850.	5.5	37
158	HPV DNA Detection and Typing in Cervical Scrapes. , 2005, 119, 101-114.		36
159	Cancer Risk Stratification of Anal Intraepithelial Neoplasia in Human Immunodeficiency Virusâ€“Positive Men by Validated Methylation Markers Associated With Progression to Cancer. Clinical Infectious Diseases, 2021, 72, 2154-2163.	5.8	36
160	Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands. International Journal of Cancer, 2005, 115, 268-275.	5.1	35
161	Methylation-mediated repression of PRDM14 contributes to apoptosis evasion in HPV-positive cancers. Carcinogenesis, 2014, 35, 2611-2618.	2.8	35
162	CADM1 and MAL methylation status in cervical scrapes is representative of the most severe underlying lesion in women with multiple cervical biopsies. International Journal of Cancer, 2016, 138, 463-471.	5.1	35

#	Article	IF	Citations
163	p53 immunoexpression in non-malignant oral mucosa adjacent to oral squamous cell carcinoma: potential consequences for clinical management. , 2000, 191, 132-137.		34
164	Triage using HPV-testing in persistent borderline and mildly dyskaryotic smears: Proposal for new guidelines. International Journal of Cancer, 2005, 116, 122-129.	5.1	34
165	Early detection of CIN3 and cervical cancer during long-term follow-up using HPV/Pap smear co-testing and risk-adapted follow-up in a locally organised screening programme. International Journal of Cancer, 2014, 135, 1408-1416.	5.1	33
166	Methylation Levels of CADM1, MAL, and MIR124-2 in Cervical Scrapes for Triage of HIV-Infected, High-Risk HPV-Positive Women in Kenya. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 311-318.	2.1	33
167	Three-tiered score for Ki-67 and p16^{ink4a} improves accuracy and reproducibility of grading CIN lesions. Journal of Clinical Pathology, 2018, 71, 981-988.	2.0	33
168	Whole-Genome Sequencing and Variant Analysis of Human Papillomavirus 16 Infections. Journal of Virology, 2017, 91, .	3.4	33
169	Apoptosis in B-cell lymphomas and reactive lymphoid tissues always involves activation of caspase 3 as determined by a newin situ detection method. Journal of Pathology, 2002, 196, 307-315.	4.5	32
170	Long-term CIN3+ risk of HPV positive women after triage with FAM19A4/miR124-2 methylation analysis. Gynecologic Oncology, 2019, 154, 368-373.	1.4	32
171	Large cell lymphomas. I. Differential diagnosis of centroblastic and b-immunoblastic subtypes by morphometry on histologic preparations. Cancer, 1984, 54, 2082-2087.	4.1	31
172	Non-random allelic losses at 3p, 11p and 13q during HPV-mediated immortalization and concomitant loss of terminal differentiation of human keratinocytes. , 1998, 76, 412-417.		31
173	Absence oftpr-metand expression ofc-metin human gastric mucosa and carcinoma. Journal of Pathology, 2001, 194, 428-435.	4.5	31
174	Methylation status of the E2 binding sites of HPV16 in cervical lesions determined with the LuminexÂ® xMAPâ„¢ system. Virology, 2012, 422, 357-365.	2.4	30
175	Human Papillomavirus Detection by Penile Site in Young Men From Kenya. Sexually Transmitted Diseases, 2007, 34, 928-934.	1.7	29
176	Human papillomavirus infection in a populationâ€based sample of women in Algiers, Algeria. International Journal of Cancer, 2011, 128, 2224-2229.	5.1	29
177	Longitudinal assessment of DNA methylation changes during HPVE6E7-induced immortalization of primary keratinocytes. Epigenetics, 2015, 10, 73-81.	2.7	29
178	Genomeâ€wide microRNA analysis of HPVâ€positive selfâ€samples yields novel triage markers for early detection of cervical cancer. International Journal of Cancer, 2019, 144, 372-379.	5.1	29
179	The expression pattern of contractile and intermediate filament proteins in developing skeletal muscle and rhabdomyosarcoma of childhood: Diagnostic and prognostic utility. Journal of Pathology, 1994, 174, 283-292.	4.5	28
180	HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test. British Journal of Cancer, 2017, 117, 1557-1561.	6.4	28

#	Article	IF	Citations
181	Squamous Cell Carcinoma of the Penis: Premalignant Lesions. Scandinavian Journal of Urology and Nephrology, 2000, 34, 187-188.	1.4	27
182	HPV testing in cervical screening. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2006, 20, 253-266.	2.8	27
183	Differential In Vitro Immortalization Capacity of Eleven, Probable High-Risk Human Papillomavirus Types. Journal of Virology, 2014, 88, 1714-1724.	3.4	27
184	Epstein-Barr virus is present in neoplastic cytotoxic T cells in extranodal, and predominantly in B cells in nodal T non-Hodgkin lymphomas. Journal of Pathology, 2000, 191, 400-406.	4.5	26
185	Gene expression profiling to identify markers associated with deregulated hTERT in HPVâ€transformed keratinocytes and cervical cancer. International Journal of Cancer, 2008, 122, 877-888.	5.1	26
186	Postâ€treatment CIN: Randomised clinical trial using hrHPV testing for prediction of residual/recurrent disease. International Journal of Cancer, 2009, 124, 889-895.	5.1	26
187	Classification of highâ€grade cervical intraepithelial neoplasia by p16^{ink4a}, Kiâ€67, <scp>HPV E4</scp> and <scp>FAM19A4</scp>/<scp>miR124</scp>â€2 methylation status demonstrates considerable heterogeneity with potential consequences for management. International Journal of Cancer, 2021, 149, 707-716.	5.1	26
188	Host Cell Deoxyribonucleic Acid Methylation Markers for the Detection of High-grade Anal Intraepithelial Neoplasia and Anal Cancer. Clinical Infectious Diseases, 2019, 68, 1110-1117.	5.8	25
189	Immortalization capacity of HPV types is inversely related to chromosomal instability. Oncotarget, 2016, 7, 37608-37621.	1.8	25
190	Clinical Regression of High-Grade Cervical Intraepithelial Neoplasia Is Associated With Absence of FAM19A4/miR124-2 DNA Methylation (CONCERVE Study). Journal of Clinical Oncology, 2022, 40, 3037-3046.	1.6	25
191	Five-Year Cervical (Pre)Cancer Risk of Women Screened by HPV and Cytology Testing. Cancer Prevention Research, 2015, 8, 502-508.	1.5	24
192	The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples. International Journal of Cancer, 2016, 139, 691-699.	5.1	23
193	Six-Month Incidence and Persistence of Oral HPV Infection in HIV-Negative and HIV-Infected Men Who Have Sex with Men. PLoS ONE, 2014, 9, e98955.	2.5	23
194	Pearly penile papules: Still no reason for uneasiness. Journal of the American Academy of Dermatology, 2003, 49, 50-54.	1.2	22
195	Follow-up of high-risk HPV positive women by combined cytology and bi-marker CADM1/MAL methylation analysis on cervical scrapes. Gynecologic Oncology, 2015, 137, 55-59.	1.4	22
196	Aberrant methylation-mediated silencing of microRNAs contributes to HPV-induced anchorage independence. Oncotarget, 2016, 7, 43805-43819.	1.8	22
197	Noncutaneous T-cell lymphomas recognition of a lymphoma type (large cell anaplastic) with a relatively favorable prognosis. Cancer, 1993, 71, 2604-2612.	4.1	21
198	Primary human papillomavirus DNA screening for cervical cancer prevention: Can the screening interval be safely extended?. International Journal of Cancer, 2015, 137, 420-427.	5.1	21

#	Article	IF	Citations
199	Acquisition and Persistence of Human Papillomavirus 16 (HPV-16) and HPV-18 Among Men With High-HPV Viral Load Infections in a Circumcision Trial in Kisumu, Kenya. Journal of Infectious Diseases, 2015, 211, 811-820.	4.0	21
200	Molecular heterogeneity in human papillomavirusâ€dependent and â€independent vulvar carcinogenesis. Cancer Medicine, 2018, 7, 4542-4553.	2.8	21
201	IsChlamydia pneumoniaepresent in the central nervous system of multiple sclerosis patients?. Annals of Neurology, 2000, 48, 399-399.	5.3	20
202	Molecular targeted therapies for diffuse large Bâ€cell lymphoma based on apoptosis profiles. Journal of Pathology, 2010, 220, 509-520.	4.5	20
203	Presence of human papillomavirus inÂsemen of healthy men isÂfirmly associated with HPV infections ofÂtheÂpenile epithelium. Fertility and Sterility, 2015, 104, 838-844.e8.	1.0	20
204	Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNA-positive women. Journal of Clinical Virology, 2015, 67, 59-66.	3.1	20
205	The use of molecular markers for cervical screening of women living with HIV in South Africa. Aids, 2019, 33, 2035-2042.	2.2	20
206	IL-1Bpromoter polymorphism and Epstein-Barr virus in Dutch patients with gastric carcinoma. International Journal of Cancer, 2003, 107, 866-867.	5.1	19
207	High-risk human papillomavirus seems not involved in DES-related and of limited importance in nonDES related clear-cell carcinoma of the cervix. Gynecologic Oncology, 2011, 122, 297-302.	1.4	19
208	Twelve-month incidence and clearance of oral HPV infection in HIV-negative and HIV-infected men who have sex with men: the H2M cohort study. BMC Infectious Diseases, 2014, 14, 668.	2.9	19
209	How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands. Vaccine, 2009, 27, 5111-5119.	3.8	18
210	Novel molecular subtypes of cervical cancer â€" potential clinical consequences. Nature Reviews Clinical Oncology, 2017, 14, 397-398.	27.6	18
211	Detection of hypermethylated genes as markers for cervical screening in women living with HIV. Journal of the International AIDS Society, 2018, 21, e25165.	3.0	18
212	Triage of high-risk HPV-positive women in population-based screening by miRNA expression analysis in cervical scrapes; a feasibility study. Clinical Epigenetics, 2018, 10, 76.	4.1	18
213	Differential presence of Papillomavirus variants in cervical cancer: An analysis for HPV33, HPV45 and HPV58. Infection, Genetics and Evolution, 2013, 13, 96-104.	2.3	17
214	Selection of women at risk for cervical cancer in an HIV-infected South African population. Aids, 2017, 31, 1945-1953.	2.2	17
215	Performance of <scp>DNA</scp> methylation analysis of <scp>ASCL1</scp>, <scp>LHX8</scp>, <scp>ST6GALNAC5</scp>, <scp>GHSR</scp>, <scp>ZIC1</scp> and <scp>SST</scp> for the triage of <scp>HPV</scp>â€positive women: Results from a Dutch primary <scp>HPV</scp>â€based screening cohort. International Journal of Cancer, 2022, 150, 440-449.	5.1	17
216	Telomerase activity in high-grade cervical lesions is associated with allelic imbalance at 6Q14-22. International Journal of Cancer, 2003, 105, 577-582.	5.1	16

#	Article	IF	Citations
217	Good performance of p16/kiâ€67 dualâ€stained cytology for surveillance of women treated for highâ€grade CIN. International Journal of Cancer, 2017, 140, 423-430.	5.1	16
218	Comparison of HPV and cytology triage algorithms for women with borderline or mild dyskaryosis in populationâ€based cervical screening (VUSAâ€screen study). International Journal of Cancer, 2010, 126, 2175-2181.	5.1	15
219	Posttreatment Assessment of Women at Risk of Developing High-Grade Cervical Disease. Journal of Lower Genital Tract Disease, 2014, 18, 338-343.	1.9	15
220	Reliable identification of women with CIN3+ using hrHPV genotyping and methylation markers in a cytologyâ€screened referral population. International Journal of Cancer, 2019, 144, 160-168.	5.1	15
221	Effect of the bivalent HPV vaccine on viral load of vaccine and non-vaccine HPV types in incident clearing and persistent infections in young Dutch females. PLoS ONE, 2019, 14, e0212927.	2.5	15
222	Evaluation of six methylation markers derived from genome-wide screens for detection of cervical precancer and cancer. Epigenomics, 2020, 12, 1569-1578.	2.1	15
223	High Whole-Genome Sequence Diversity of Human Papillomavirus Type 18 Isolates. Viruses, 2018, 10, 68.	3.3	14
224	Expression of p16 and HPV E4 on biopsy samples and methylation of FAM19A4 and miR124â€2 on cervical cytology samples in the classification of cervical squamous intraepithelial lesions. Cancer Medicine, 2020, 9, 2454-2461.	2.8	13
225	Risk-stratification of HPV-positive women with low-grade cytology by FAM19A4/miR124-2 methylation and HPV genotyping. British Journal of Cancer, 2022, 126, 259-264.	6.4	13
226	Role ofFAM19A4/miR124-2methylation analysis in predicting regression or non-regression of CIN2/3 lesions: a protocol of an observational longitudinal cohort study. BMJ Open, 2019, 9, e029017.	1.9	12
227	Male Circumcision Reduces Penile HPV Incidence and Persistence: A Randomized Controlled Trial in Kenya. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1139-1148.	2.5	12
228	The Age Distribution of Type-Specific High-Risk Human Papillomavirus Incidence in Two Population-Based Screening Trials. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 111-118.	2.5	11
229	HPV type-related chromosomal profiles in high-grade cervical intraepithelial neoplasia. BMC Cancer, 2012, 12, 36.	2.6	10
230	Why follow-back studies should be interpreted cautiously: The case of an HPV-negative cervical lesion. Cancer Cytopathology, 2016, 124, 66-67.	2.4	10
231	Impact of Collection Volume and DNA Extraction Method on the Detection of Biomarkers and HPV DNA in First-Void Urine. Molecules, 2021, 26, 1989.	3.8	10
232	Management of HPVâ€positive women in cervical screening using results from two consecutive screening rounds. International Journal of Cancer, 2019, 144, 2339-2346.	5.1	9
233	Stratifying HPVâ€positive women for CIN3+ risk after one and two rounds of HPVâ€based screening. International Journal of Cancer, 2017, 141, 1551-1560.	5.1	7
234	HPV16-Related Cervical Cancers and Precancers Have Increased Levels of Host Cell DNA Methylation in Women Living with HIV. International Journal of Molecular Sciences, 2018, 19, 3297.	4.1	7

#	Article	IF	Citations
235	Defining hrHPV genotypes in cervical intraepithelial neoplasia by laser capture microdissection supports reflex triage of self-samples using HPV16/18 and FAM19A4/miR124-2 methylation. Gynecologic Oncology, 2018, 151, 311-318.	1.4	7
236	Complementarity between miRNA expression analysis and DNA methylation analysis in hrHPV-positive cervical scrapes for the detection of cervical disease. Epigenetics, 2019, 14, 558-567.	2.7	7
237	Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screenâ€detected cervical precancer. International Journal of Cancer, 2021, 148, 320-328.	5.1	7
238	Bortezomib Induces Caspase-9-Mediated Apoptosis through Activation of the BH3-Only Proteins Noxa, Bik and Puma In Both ALK-Positive and ALK-Negative Anaplastic Large Cell Lymphoma Cells. Blood, 2010, 116, 2847-2847.	1.4	7
239	Higher HPV16 and HPV18 Penile Viral Loads Are Associated With Decreased Human Papillomavirus Clearance in Uncircumcised Kenyan Men. Sexually Transmitted Diseases, 2016, 43, 572-578.	1.7	6
240	HPV16 variant analysis in primary and recurrent CIN2/3 lesions demonstrates presence of the same consensus variant. Papillomavirus Research (Amsterdam, Netherlands), 2019, 7, 168-172.	4.5	6
241	Characterization of cervical biopsies of women with HIV and HPV co-infection using p16ink4a, ki-67 and HPV E4 immunohistochemistry and DNA methylation. Modern Pathology, 2020, 33, 1968-1978.	5.5	6
242	Characterisation of anal intraepithelial neoplasia and anal cancer in <scp>HIV</scp>â€positive men by immunohistochemical markers p16, Kiâ€67, <scp>HPVâ€E4</scp> and <scp>DNA</scp> methylation markers. International Journal of Cancer, 2021, 149, 1833-1844.	5.1	6
243	Direct bisulphite conversion of cervical samples for DNA methylation analysis. Epigenetics, 2022, 17, 1173-1179.	2.7	6
244	Follow-up after treatment for cervical intraepithelial neoplasia. BMJ, The, 2012, 345, e7186-e7186.	6.0	5
245	Cervical cancerâ€"should we abandon cytology for screening?. Nature Reviews Clinical Oncology, 2012, 9, 558-559.	27.6	5
246	ALK-negative anaplastic large cell lymphoma is sensitive to bortezomib through Noxa upregulation and release of Bax from Bcl-2. Haematologica, 2015, 100, e365-e368.	3.5	5
247	Human Papillomavirus Triage of Women With Atypical Squamous Cells of Undetermined Significanceâ€"Reduction of Overtreatment Needed. JAMA Oncology, 2017, 3, 1310.	7.1	5
248	Anal HPV 16 and 18 viral load: A comparison between HIVâ€negative and â€positive MSM and association with persistence. Journal of Medical Virology, 2018, 90, 76-83.	5.0	5
249	HPV infections and flat penile lesions of the penis in men who have sex with men. Papillomavirus Research (Amsterdam, Netherlands), 2019, 8, 100173.	4.5	5
250	Different risk factor patterns for highâ€grade and lowâ€grade intraepithelial lesions on the cervix among HPVâ€positive and HPVâ€negative young women. International Journal of Cancer, 1998, 76, 613-619.	5.1	5
251	Chemotherapy-Refractory Diffuse Large B-Cell Lymphomas (DLBCL) Are Effectively Killed by Ofatumumab-Induced Complement-Mediated Cytoxicity.. Blood, 2007, 110, 2346-2346.	1.4	5
252	Prevention of cervical cancer: Where immunology meets diagnostics. Immunology Letters, 2009, 122, 126-127.	2.5	4

#	Article	IF	Citations
253	HPV Screening: Available Data and Recommendations for Clinical Practice. Current Cancer Therapy Reviews, 2010, 6, 104-109.	0.3	4
254	Arguments in favor of HPV testing for cervical screening and post-treatment CIN2+ monitoring. Expert Review of Molecular Diagnostics, 2014, 14, 245-248.	3.1	4
255	Evaluation of FAM19A4/miR124â€2 methylation performance in the management of <scp>CIN3</scp> diagnosed pregnant women. International Journal of Cancer, 0, , .	5.1	4
256	FAM19A4/miR124-2 Methylation Testing and Human Papillomavirus (HPV) 16/18 Genotyping in HPV-Positive Women Under the Age of 30 Years. Clinical Infectious Diseases, 2023, 76, e827-e834.	5.8	4
257	Colposcopic Characteristics of High-Risk Human Papillomavirus-Related Cervical Lesions. Journal of Lower Genital Tract Disease, 2010, 14, 49-55.	1.9	3
258	A new approach to cervical screening. Lancet Oncology, The, 2011, 12, 612-613.	10.7	3
259	Developing and Standardizing Human Papillomavirus Tests. , 2020, , 111-130.		3
260	Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: The ageâ€related patterns for highâ€risk and lowâ€risk types. International Journal of Cancer, 2000, 87, 221-227.	5.1	3
261	Highâ€risk HPV testing in women with borderline and mild dyskaryosis: longâ€term followâ€up data and clinical relevance. Journal of Pathology, 2001, 195, 300-306.	4.5	3
262	Cervical cancer prevention: who should receive vaccination?. Nature Clinical Practice Oncology, 2008, 5, 12-13.	4.3	2
263	Small-Molecule XIAP Antagonist Restores Caspase-9-Mediated Apoptosis in XIAP-Positive Diffuse Large B-Cell Lymphoma Cells.. Blood, 2007, 110, 803-803.	1.4	2
264	Women with a positive high-risk human papillomavirus (HPV) test remain at increased risk of HPV infection and cervical precancer â‰¥15 years later. Tumour Virus Research, 2022, 14, 200240.	3.8	2
265	Infection to Cancerâ€”Finding Useful Biomarkers for Predicting Risk of Progression to Cancer. , 2020, , 269-282.		1
266	Molecular Biology of Penile Cancer. , 2011, , 13-25.		1
267	Post-treatment monitoring by ASCL1/LHX8 methylation analysis in women with HIV treated for cervical intraepithelial neoplasia grade 2/3. Aids, 2022, Publish Ahead of Print, .	2.2	1
268	Clinical Validation of the Fully Automated NeuMoDx HPV Assay for Cervical Cancer Screening. Viruses, 2022, 14, 893.	3.3	1
269	Tobacco, condom use and regression of CIN lesions. International Journal of Cancer, 2004, 112, 165-165.	5.1	0
270	Molecular Markers for Cervical Cancer. , 2006, , 73-81.		0

#	Article	IF	Citations
271	Primary Screening by Human Papillomavirus Testing: Development, Implementation, and Perspectives. , 2020, , 245-268.		0
272	Incidence and clearance of penile human papillomavirus infection among circumcised Kenyan men. International Journal of STD and AIDS, 2020, 31, 1202-1211.	1.1	0
273	Risk of Cervical Intraepithelial Neoplasia Grade 3 or Worse in HPV-Positive Women with Normal Cytology and Five-Year Type Concordance: A Randomized Comparison. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 485-491.	2.5	0
274	Profiling of Caspase Signaling Pathways Predicts Clinical Response to Chemotherapy in Diffuse Large B-Cell Lymphomas.. Blood, 2004, 104, 1544-1544.	1.4	0
275	HPV Typing Comparison of Different Molecular Assays. , 2004, , 640-645.		0
276	Promiscuous Behavior of HPV16E6 Specific T Cell Receptor Beta Chains Hampers Functional Expression in TCR Transgenic T Cells, Which Can Be Restored in Part by Genetic Modification. Analytical Cellular Pathology, 2010, 32, 43-56.	1.4	0
277	Enteropathy-Associated T-Cell Lymphoma: a Clinical Prognostic Model to Identify High Risk Patients. Blood, 2010, 116, 3092-3092.	1.4	0
278	hsTRAIL/Apo2L Induces Apoptosis in Enteropathy-Associated T-Cell Lymphoma. Blood, 2011, 118, 1665-1665.	1.4	0
279	Bortezomib Restores Defective Apoptosis by Upregulation of Noxa in Enteropathy-Associated T-Cell Lymphoma. Blood, 2011, 118, 2722-2722.	1.4	0
280	Imbalance in Alternative Splicing of MCL-1 Inhibits Apoptosis in Diffuse Large B-Cell Lymphoma. Blood, 2014, 124, 5424-5424.	1.4	0